EO2463

BIOLOGICAL2 trials

Sponsors

Enterome

Conditions

Follicular LymphomaIndolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Lymphoma)Marginal Zone Lymphoma

Phase 1

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

RecruitingNCT04669171

EnteromeFollicular Lymphoma, Marginal Zone Lymphoma

Start: 2021-07-05End: 2034-05-30Target: 80Updated: 2026-01-30

A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients with indolent Non-Hodgkin's Lymphoma.

RecruitingCTIS2023-509254-58-00

EnteromeIndolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Lymphoma)

Start: 2021-05-31Target: 29Updated: 2026-01-12

Related Papers

<i>EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study</i>

Blood2024-11-05

<i>EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab</i>

Blood2024-11-05

Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).

Journal of Clinical Oncology2024-06-011 citations

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY

Hematological Oncology2023-06-01

A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).

Journal of Clinical Oncology2022-06-011 citations